- Describe the spectrum of vascular, cardiac and renal risk in patients with type 2 diabetes, and the unmet clinical need in these patients.
- Create an algorithm of where to use SGLT2 inhibitors in the management of patients with type 2 diabetes with and without established vascular disease to reduce cardiovascular and renal outcomes.
- Describe the current clinical practice guidelines that are specific to SGLT2 inhibitors in diabetes, and the clinical implications of new trials.
This activity has been determined by the Royal College to meet the criteria for a Personal Learning Project in Section 2 credits under the Maintenance of Certification (MOC) Program. Remember to visit MAINPORT to record your learning and outcomes.
Dr. Mohamed Al-Omran
|01:18||Chapter 1: Unmet needs of cardiovascular and renal protection in diabetes
Dr. Subodh Verma
|14:14||Chapter 2: DECLARE-TIMI 58 Main Results
Dr. Stephen Wiviott
|26:12||Chapter 3: Pump, Pipes, Filter: How do we synthesize the SGLT2i data?
Dr. Subodh Verma
|42:58||Chapter 4: Clinical implications of the DECLARE-TIMI 58 Trial
Dr. Lawrence Leiter
MD, MSc, FRCSC
Head of Vascular Surgery, St. Michael’s Hospital
Professor of Surgery, and, Pharmacology and Toxicology, University of Toronto
MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St. Michael’s Hospital
Professor of Surgery and Pharmacology & Toxicology, University of Toronto
Canada Research Chair in Cardiovascular Surgery
Stephen D. Wiviott
Cardiologist, Brigham and Women’s Hospital
Associate Professor of Medicine,
Harvard Medical School
Lawrence A. Leiter
MD, FRCPC, FACP, FACE, FAHA, FACC
Endocrinologist, St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences,
University of Toronto,
This program has received an educational grant from AstraZeneca and is only for health care professionals.